"The survival gains documented in this report validate decades of investment in cancer immunology. But they also underscore how much work remains:\n\nExpand immunotherapy to more cancer types: While melanoma and lung cancer have seen dramatic gains, many cancers remain resistant to current immunotherapies. The five-year survival rate for pancreatic cancer, for example, remains at just 13%, and uterine corpus cancer mortality has been rising for 26 consecutive years.\n\nEnsure broad access to innovation: Scientific breakthroughs only save lives if patients can benefit from them. The report shows wide variation in cancer incidence and outcomes across the U.S., reflecting geographical differences in prevention, early detection, and availability of high-quality care. Ensuring that advances in immunotherapy and precision medicine reach patients everywhere remains a critical challenge."